Pilot study to evaluate a new regimen to treat climacteric complaints with cyclic combined oestradiol valerate/medroxyprogesterone acetate.
Nineteen post-menopausal women suffering from climacteric complaints were treated with a cyclic regimen comprising 25 days on 2 mg oestradiol valerate and 5 mg medroxyprogesterone acetate daily, followed by a 5-day treatment-free interval. The mean duration of treatment was 20.2 mth. Control of bleeding was good; 9 women had slight monthly bleeding, 8 no bleeding at all, and 2 had only irregular spotting during the follow-up period. An endometrial biopsy was taken in 9 women in whom the mean duration of treatment was 30 mth. All endometrial biopsies showed an atrophic endometrium. A larger, randomized comparative study is now planned.
D000328:Adult; D002979:Climacteric / Q000187:drug effects*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D017258:Medroxyprogesterone Acetate; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D010865:Pilot Projects; D014592:Uterine Hemorrhage / Q000139:chemically induced
D004958:Estradiol; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone